Assessment and Management of Thiamine Status

Laboratory Assessment

Measuring red blood cell (RBC) or whole‑blood thiamine diphosphate (ThDP) by high‑performance liquid chromatography (HPLC) is the most reliable method for evaluating thiamine status, because virtually all circulating ThDP resides in erythrocytes, making plasma thiamine measurements unreliable. 1, 2
RBC or whole‑blood ThDP is the preferred biomarker for thiamine status assessment in clinical practice. 1, 2
Plasma thiamine measurement is not useful for status assessment, as plasma contains only trace amounts of ThDP. 1, 2
RBC ThDP concentrations are unaffected by systemic inflammation, providing a dependable marker in critically ill patients or those with inflammatory responses. 1, 2

Erythrocyte transketolase activity (ETKA) is an indirect functional assay that estimates ThDP saturation of thiamine‑dependent enzymes in the pentose‑phosphate pathway. 1, 2
Limitations of ETKA:
- Often unavailable in routine clinical laboratories. 1, 2
- Interpretation is difficult when transketolase synthesis is impaired (e.g., liver disease, critical illness). 1, 2
- Less reliable than direct ThDP measurement for acute clinical decision‑making. 1, 2

HPLC coupled with optical or mass‑spectrometry detection is the standard analytical technique for quantifying ThDP. 1
Pre‑analytical requirements for accurate ThDP measurement:
- Protect specimens from light during collection and storage. 1
- Maintain appropriate temperature control to preserve analyte stability. 1
- Use whole blood or packed erythrocytes; plasma alone must not be used. 1, 2

Initiation of thiamine therapy should not be delayed while awaiting laboratory confirmation of deficiency. 1, 2
Thiamine body stores can become depleted within approximately 20 days of insufficient oral intake. 1, 2
Untreated deficiency can lead to irreversible neurological injury (e.g., Wernicke’s encephalopathy) within days. 1, 2
An immediate therapeutic trial of thiamine supplementation is recommended to assess clinical benefit when deficiency is suspected. 1, 2

Elevated alpha‑ketoglutarate levels may support the diagnosis of thiamine deficiency. 1
Elevated glyoxylate levels may also indicate thiamine deficiency. 1
These metabolites reflect impaired glucose metabolism due to dysfunction of thiamine‑dependent enzymes, but they are not specific for thiamine deficiency. 1, 2

Patients receiving prolonged parenteral nutrition should have thiamine status evaluated. 1

The American College of Nutrition recommends measuring thiamine levels in patients with suspected deficiency in high-risk contexts, such as cardiomyopathy with prolonged diuretic treatment, using RBC or whole blood thiamine diphosphate (ThDP) 3, 4
RBC or whole blood ThDP is the recommended measurement method, with a Grade A recommendation 3, 5
Plasma measurement is not useful since virtually all circulating ThDP is in erythrocytes 4

Thiamine deficiency can present with neurological symptoms, such as apathy, decreased short-term memory, and confusion, particularly in patients with malnutrition, poor oral intake, and chronic alcohol consumption 3, 6
Thiamine levels are particularly useful in monitoring patients with heart failure, with deficiency found in 6% of ambulatory patients 3
Critically ill patients are at high risk of thiamine deficiency or depletion, with >90% of patients affected 3

The American College of Nutrition recommends treating mild thiamine deficiency with 10 mg/day thiamine for a week, followed by 3-5 mg/day for at least 6 weeks 5
High suspicion or proven deficiency should be treated with 200 mg, 3 times a day, IV 5
Maintenance dose after proven deficiency is 50-100 mg/day, orally 5

Thiamine reserves can be depleted as early as 20 days of inadequate oral intake 3
Treatment should not be delayed by waiting for laboratory results; a thiamine supplementation trial should be performed to assess clinical benefit 4
Thiamine has no established upper limit for toxicity, with excess being excreted in urine 5